tirzepatide cvot trial A comparison of the effects of and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT In patients with type 2

Compounded HRT becomes clinically relevant when FDA-approved options are insufficient for a specific patients situation

Among the 60 participants treated with GSBR-1290, only one (2.8%, from the T2DM group) discontinued the study due to drug-related adverse events (AEs)

The end result of the synergistic action of Setria and LipoCellTech technology is an increase in plasma but also intracellular concentration of glutathione

Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet , 2021;397(10278):971984

36 Months Many people reach their strongest, most predictable results in this period